Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide versus semaglutide in nonalcoholic fatty liver disease
2020-005136-30Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Efinopegdutide with Semaglutide (2 arms). Primary endpoint: Mean relative reduction from baseline in liver fat content after 24 weeks. Started Jun 2021; status: completed.
02
Drugs
efinopegdutidesemaglutide
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2020-005136-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005136-30.